Get the Stockscreener App
17.55
4.20%
-0.77
Tenax Therapeutics Inc stock is traded at $17.55, with a volume of 1.05M.
It is down -4.20% in the last 24 hours and up +66.35% over the past month.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
See More
Previous Close:
$18.32
Open:
$18.15
24h Volume:
1.05M
Relative Volume:
1.17
Market Cap:
$465.52M
Revenue:
-
Net Income/Loss:
$-57.91M
P/E Ratio:
-12.54
EPS:
-1.3991
Net Cash Flow:
$-38.14M
1W Performance:
+13.52%
1M Performance:
+66.35%
6M Performance:
+31.95%
1Y Performance:
+203.98%
1-Day Range:
$17.00
$18.31
1-Week Range:
$15.28
$19.40
52-Week Range:
$5.7663
$19.40
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
17.55 | 465.52M | 0 | -57.91M | -38.14M | -1.3991 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-25 | Initiated | Piper Sandler | Overweight |
| Oct-24-24 | Initiated | Leerink Partners | Outperform |
| Oct-14-24 | Initiated | Guggenheim | Buy |
| Sep-30-24 | Initiated | William Blair | Outperform |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
FMR LLC reports 3.94M-share holding in Tenax Therapeutics (TENX) - Stock Titan
Tenax Therapeutics: 'Hold' TNX-103 Data August 2026But With Caution Ahead (NASDAQ:TENX) - Seeking Alpha
LifeSci Capital Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Price to sales forward of Tenax Therapeutics, Inc. – NASDAQ:TENX - TradingView
Tenax lures three new hires with 160,000 stock options - Stock Titan
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 - Investing News Network
(TENX) Risk Channels and Responsive Allocation - Stock Traders Daily
Tenax Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Tenax Therapeutics to Present Phase 3 LEVEL Trial Results for Levosimendan in PH-HFpEF at ESC Congress 2026 - Minichart
Tenax Therapeutics Price Target Maintained With a $27.00/Share by Chardan Capital - Moomoo
Tenax Therapeutics highlights key Phase 3 LEVEL trial - TipRanks
Late-breaking ESC 2026 spot for Tenax (TENX) Phase 3 LEVEL trial data - Stock Titan
Tenax Therapeutics to present Phase 3 trial results at ESC By Investing.com - Investing.com Australia
Tenax Therapeutics to present Phase 3 trial results at ESC - Investing.com
Tenax and Orion Secure Long-Term Levosimendan Supply Deal - The Globe and Mail
TENX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Sharp Stock RallyAnalyst Drop Coverage - dars.gov.et
Tenax Therapeutics Extends Us Regulatory Approval Deadline To December 31, 2035 Via Sixth Amendment To Orion LicenseSEC Filing - TradingView
Tenax Therapeutics, Inc. has extended the deadline for U.S. regulatory approval to December 31, 2035, through the sixth amendment to its licensing agreement with Orion. - Bitget
Tenax Therapeutics (NASDAQ: TENX) deepens Orion deal, extends approval deadline to 2035 - Stock Titan
Tenax Therapeutics Updates Executive and Employee Severance Protections - TipRanks
Tenax Therapeutics (TENX) expands executive and employee severance, CIC plans - Stock Titan
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 2000 Index - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 2000 Value Benchmark - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 3000E Index - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 2000 Dynamic Index - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell Microcap Index - marketscreener.com
Tenax Therapeutics, Inc. Actuals & Estimates (NASDAQ:TENX) - TradingView
Tenax Therapeutics, Inc. Actuals & Estimates (FWB:YBO0) - TradingView
Tenax Therapeutics, Inc. Actuals & Estimates (BOATS:TENX) - TradingView
TENX Forecast — Price Target — Prediction for 2027 - TradingView
TENX Reiterates by Cantor Fitzgerald -- Price Target Maintained at $35.00 - GuruFocus
Here's Why We're Not Too Worried About Tenax Therapeutics' (NASDAQ:TENX) Cash Burn Situation - Moomoo
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), Abbott Laboratories (ABT) and AbbVie (ABBV) - The Globe and Mail
TENX Maintained by Guggenheim -- Price Target Raised to $40 - GuruFocus
TENX Initiated Coverage by Chardan Capital -- Rating Set as Buy - GuruFocus
Guggenheim raises Tenax Therapeutics stock price target on trial confidence By Investing.com - Investing.com Nigeria
Tenax Therapeutics Is Maintained at Buy by Guggenheim - Moomoo
Guggenheim raises Tenax Therapeutics stock price target on trial confidence - Investing.com
(TENX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Tenax Therapeutics (TENX) Edges Higher at $12.0: Testing Key Resistance in Biotech SectorRetail Volume - dars.gov.et
Tenax Therapeutics Inc (TENX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tenax Therapeutics Inc (TENX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tenax Therapeutics Inc (TENX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tenax Therapeutics Inc (TENX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tenax Therapeutics Inc (TENX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tenax Therapeutics Inc (TENX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tenax Therapeutics (TENX) Surges 4.8% as Momentum Builds Above Key SupportEarnings Quality Factor - newsline.com
Tenax Therapeutics Inc (TENX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tenax Therapeutics Inc (TENX) Institutional Confidence - TradingKey
TENX Maintained by Piper Sandler -- Price Target Raised to $50 - GuruFocus
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tenax Therapeutics Inc Stock (TENX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rich Stuart | Chief Medical Officer |
Dec 08 '25 |
Buy |
10.10 |
2,500 |
25,250 |
5,000 |
| Rich Stuart | Chief Medical Officer |
Dec 04 '25 |
Buy |
9.20 |
2,500 |
22,998 |
2,500 |
| Rich Stuart | Chief Medical Officer |
Dec 03 '25 |
Buy |
9.08 |
1,500 |
13,618 |
2,766 |
| Rich Stuart | Chief Medical Officer |
Dec 02 '25 |
Buy |
9.01 |
1,000 |
9,006 |
1,266 |
| Giordano Christopher Thomas | CEO |
Nov 18 '25 |
Buy |
7.75 |
1,612 |
12,500 |
1,612 |
| Giordano Christopher Thomas | CEO |
Nov 20 '25 |
Buy |
7.59 |
538 |
4,083 |
2,605 |
| Giordano Christopher Thomas | CEO |
Nov 19 '25 |
Buy |
7.51 |
455 |
3,417 |
2,067 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.25 |
6,000 |
43,490 |
5,000 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.34 |
2,000 |
14,674 |
2,000 |
| Almenoff June Sherie | Director |
Nov 18 '25 |
Buy |
7.52 |
1,900 |
14,280 |
1,993 |
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):